Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N
6
-methyladenosine (m
6
A) regulators are involved in the progression of various cancers via regulating m
6
A modification. However, the potential role and mechanism of the m
6
A modification in
osteosarcoma
remains obscure. In this study, WTAP was found to be highly expressed in
osteosarcoma
tissue and it was an independent prognostic factor for overall survival in
osteosarcoma
. Functionally, WTAP, as an oncogene, was involved in the proliferation and metastasis of
osteosarcoma
in vitro and vivo. Mechanistically, M
6
A dot blot, RNA-seq and MeRIP-seq, MeRIP-qRT-PCR and luciferase reporter assays showed that
HMBOX1
was identified as the target gene of WTAP, which regulated
HMBOX1
stability depending on m
6
A modification at the 3'UTR of
HMBOX1
mRNA. In addition,
HMBOX1
expression was downregulated in
osteosarcoma
and was an independent prognostic factor for overall survival in
osteosarcoma
patients. Silenced
HMBOX1
evidently attenuated shWTAP-mediated suppression on
osteosarcoma
growth and metastasis in vivo and vitro. Finally, WTAP/
HMBOX1
regulated
osteosarcoma
growth and metastasis via PI3K/AKT pathway. In conclusion, this study demonstrated the critical role of the WTAP-mediated m
6
A modification in the progression of
osteosarcoma
, which could provide novel insights into
osteosarcoma
treatment.
...
PMID:WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m
6
A-dependent manner. 3281 62
